3 Months Ended

Document And Entity Information - shares

Mar. 31, 2020
Document Information [Line Items]
Entity Registrant Name GeoVax Labs, Inc.
Entity Central Index Key 0000832489
Current Fiscal Year End Date --12-31
Entity Filer Category Non-accelerated Filer
Entity Current Reporting Status Yes
Entity Emerging Growth Company false
Entity Small Business true
Entity Interactive Data Current Yes
Entity Common Stock, Shares Outstanding (in shares)
Entity Shell Company false
Document Type 10-Q
Document Period End Date Mar. 31,
Document Fiscal Year Focus 2020 2020
Document Fiscal Period Focus Q1
Amendment Flag false
Title of 12(g) Security Common Stock $.001 par value
May 05, 2020

13,819,101
 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
ASSETS
Cash and cash equivalents
Grant funds and other receivables
Prepaid expenses and other current assets
Total current assets
Property and equipment, net (Note 5)
Deposits
Total assets
Current liabilities:
Accounts payable
Accrued expenses (Note 6)
Current portion of notes payable (Note 7)
Total current liabilities
Note payable, net of current portion (Note 7)
Total liabilities
Commitments (Note 8)
Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value (Note 9): Authorized shares – 10,000,000 Issued and
outstanding
Common stock, shares – 400
$.001 par and 2,486
value: March 31,
Authorized 2020–and
shares DecemberIssued
600,000,000 31, 2019,
and respectively
outstanding
shares – 13,791,601 and
Additional paid-in capital 299,835 at March 31, 2020 and December 31, 2019, respectively
Accumulated deficit
Total stockholders’ equity (deficiency)
Total liabilities and stockholders’ equity (deficiency)
Mar. 31, 2020 Dec. 31, 2019

$ 221,807 $ 283,341
520,509 68,603
67,895 95,320
810,211 447,264
9,612 10,606
11,010 11,010
830,833 468,880

740,829 152,653
1,917,425 1,851,040
12,048 12,500
2,670,302 2,016,193
24,781 27,243
2,695,083 2,043,436

376,095 1,932,433
13,792 300
41,189,070 39,340,224
(43,443,207) (42,847,513)
(1,864,250) (1,574,556)
$ 830,833 $ 468,880
 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) -
$ / shares
Preferred stock, par value (in dollars per share)
Preferred stock, shares authorized (in shares)
Preferred stock, shares issued (in shares)
Preferred stock, shares outstanding (in shares)
Common stock, par value (in dollars per share)
Common stock, shares authorized (in shares)
Common stock, shares issued (in shares)
Common stock, shares outstanding (in shares)
Mar. 31, 2020 Dec. 31, 2019
$ 0.01 $ 0.01
10,000,000 10,000,000
400 2,486
400 2,486
$ 0.001 $ 0.001
600,000,000 600,000,000
13,791,601 299,835
13,791,601 299,835
 3 Months Ended
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
Mar. 31, 2020
Grant and collaboration revenues $ 715,977
Operating expenses:
Research and development 808,936
General and administrative 502,345
Total operating expenses 1,311,281
Loss from operations (595,304)
Other income (expense):
Interest income 752
Interest expense (1,142)
Total other income (expense) (390)
Net loss $ (595,694)
Basic and diluted:
Net loss per common share (in dollars per share) $ (0.13)
Weighted average shares outstanding (in shares) 4,687,893
3 Months Ended
Mar. 31, 2019
$ 364,232

555,718
510,064
1,065,782
(701,550)

1,224
(1,128)
96
$ (701,454)

$ (2,851.44)
246
 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency)
(Unaudited) - USD ($)
Balance (in shares) at Dec. 31, 2018
Balance at Dec. 31, 2018
Sale of convertible preferred stock for cash (in shares)
Sale of convertible preferred stock for cash
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Net loss
Stock-based compensation expense
Balance (in shares) at Mar. 31, 2019
Balance at Mar. 31, 2019
Balance (in shares) at Dec. 31, 2019
Balance at Dec. 31, 2019
Sale of convertible preferred stock for cash (in shares)
Sale of convertible preferred stock for cash
Conversion of preferred stock to common stock (in shares)
Conversion of preferred stock to common stock
Issuance of common stock for services (in shares)
Issuance of common stock for services
Net loss
Balance (in shares) at Mar. 31, 2020
Balance at Mar. 31, 2020
Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member]
3,450 219
$ 1,971,333 $ 37,483,204
500
$ 404,250 85,750
(767) 59
$ (303,475) 303,475

26,652
3,183 278
$ 2,072,108 37,899,081
2,486 299,835
$ 1,932,433 $ 300 39,340,224
300
$ 300,000
(2,386) 13,481,349
$ (1,856,338) $ 13,481 1,842,857
10,417
$ 11 5,989

400 13,791,601
$ 376,095 $ 13,792 $ 41,189,070
Retained Earnings [Member] Total

$ (40,476,884) ###

490,000

(701,454) (701,454)
26,652

(41,178,338) (1,207,149)

(42,847,513) (1,574,556)

300,000

10,417
$ 6,000
(595,694) (595,694)

$ (43,443,207) ###
 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Changes in assets and liabilities:
Grant funds and other receivables
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Total adjustments
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Net proceeds from sale of preferred stock
Principal repayment of note payable
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
 3 Months Ended
Mar. 31, 2020 Mar. 31, 2019

$ (595,694) $ (701,454)

994 1,897
6,000 153,224

(451,906) (38,463)
27,425 (30)
654,561 267,465
237,074 384,093
(358,620) (317,361)

(4,272)
(4,272)

300,000 240,000
(2,914) (2,083)
297,086 237,917
(61,534) (83,716)
283,341 259,701
$ 221,807 $ 175,985
 Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of stock, shares issued (in shares)
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes
Payable [Member]
Convertible preferred stock (in shares)
Convertible note, value | $
Conversion of Series C Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)
Conversion of stock, shares issued (in shares)
Conversion of Series F Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)
Conversion of stock, shares issued (in shares)
 3 Months Ended
Mar. 31, 2019USD ($)shares

1,563

1,200

2,763

250
$ 250,000

587
39

180
20
 Note 1 - Description of Business
Notes to Financial Statements
Nature of Operations [Text Block]
 3 Months Ended
Mar. 31, 2020

1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company

developing human vaccines and immunotherapies against infectious diseases and cancers
 Note 2 - Basis of Presentation
Notes to Financial Statements
Basis of Accounting [Text Block]
 3 Months Ended
Mar. 31, 2020

2. The accompanying condensed consolidated financial statements at March 31, 2020 three
March 31, 2020 2019 not 10 December 31, 2019. not As described in Note 9, April 30, 2019,
 Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements
Notes to Financial Statements
Significant Accounting Policies [Text Block]
 3 Months Ended
Mar. 31, 2020

3. We disclosed in Note 2 10 December 31, 2019 no 10 There have been no three March 31,
2020, 10 December 31, 2019,
 Note 4 - Basic and Diluted Loss Per Common Share
Notes to Financial Statements
Earnings Per Share [Text Block]
 3 Months Ended
Mar. 31, 2020

4. Basic and diluted loss per common share are computed based on the weighted average
number of common shares outstanding. Common share equivalents consist of common shares
 Note 5 - Property and Equipment
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]
 3 Months Ended
Mar. 31, 2020

5. Property and equipment as shown on the accompanying Condensed Consolidated Balance

Sheets is composed of the following as of March 31, 2020 December 31, 2019: March 31, 2020
 Note 6 - Accrued Expenses
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
 3 Months Ended
Mar. 31, 2020

6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets

is composed of the following as of March 31, 2020 December 31, 2019: March 31, 2020
 Note 7 - Notes Payable
Notes to Financial Statements
Debt Disclosure [Text Block]
 3 Months Ended
Mar. 31, 2020

7. On February 28, 2018, five $50,000. 5%, $8,964 2020 $12,487 2021, $13,126 2022, $2,252
2023. three March 31, 2020 2019 $485 $621,
 Note 8 - Commitments
Notes to Financial Statements
Commitments Disclosure [Text Block]
 3 Months Ended
Mar. 31, 2020

8. Lease Agreement We lease approximately 8,400 December 31, 2022. three March 31, 2020
2019 $41,539 $40,316, $124,616 2020, $171,213 2021 $176,356 2022, may ninety Other
 Note 9 - Stockholders' Equity
Notes to Financial Statements
Preferred Stock [Text Block]
 3 Months Ended
Mar. 31, 2020

9. Preferred Stock Summary 10,000,000 $.01 may one March 31, 2020 December 31, 2019.
$1,000 three March 31, 2020 March 31, 2020 December 31, 2019 Carrying Carrying Shares
 Note 10 - Income Taxes
Notes to Financial Statements
Income Tax Disclosure [Text Block]
 3 Months Ended
Mar. 31, 2020

10. Because of our historically significant net operating losses, we have not 382
 Note 11 - Grants and Collaboration Revenue
Notes to Financial Statements
Government Grants and Contracts [Text Block]
 3 Months Ended
Mar. 31, 2020

11. We receive payments from government entities under grants from the National Institute of
Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of
 Note 12 - Subsequent Events
Notes to Financial Statements
Subsequent Events [Text Block]
 3 Months Ended
Mar. 31, 2020

12. CARES Act Paycheck Protection Program Loan On April 17, 2020, $170,200 one April 17,
2022. No 180 November 17, 2020, $9,578.16 may may
 Note 5 - Property and Equipment (Tables)
Notes Tables
Property, Plant and Equipment [Table Text Block]
 3 Months Ended
Mar. 31, 2020

March 31, 2020 December 31, 2019 Laboratory equipment $ 534,577 $ 534,577 Leasehold
improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total
 Note 6 - Accrued Expenses (Tables)
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]
 3 Months Ended
Mar. 31, 2020

March 31, 2020 December 31, 2019 Accrued management salaries $ 1,418,797 $ 1,323,483
Accrued directors’ fees 436,920 409,219 Other accrued expenses 61,708 118,338 Total
 Note 9 - Stockholders' Equity (Tables)
Notes Tables
Schedule of Preferred Stock [Table Text Block]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
 3 Months Ended
Mar. 31, 2020

March 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B
Convertible Preferred
Expiration Date Stock
Exercise 100Number
Price $ 76,095
of100 $ 76,095
Warrants Series
Series H Convertible
G September 2021 Preferred
$ 25,440Stock
48 -
Series H December 2021 1.15 217,392 Series I Aug-Dec 2024 15,000 48
 Note 2 - Basis of Presentation (Details Textual) Jan. 21, 2020 Apr. 30, 2019
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio 2,000 500
 Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)
 3 Months Ended
Mar. 31, 2020 Mar. 31, 2019
970,571 295
 Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD
($)
Property and equipment, gross
Accumulated depreciation and amortization
Property and equipment, net
Laboratory Equipment [Member]
Property and equipment, gross
Leasehold Improvements [Member]
Property and equipment, gross
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross
Mar. 31, 2020 Dec. 31, 2019
$ 661,918 $ 661,918
(652,306) (651,312)
9,612 10,606

534,577 534,577

115,605 115,605

$ 11,736 $ 11,736
 Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
Accrued management salaries
Accrued directors’ fees
Other accrued expenses
Total accrued expenses
Mar. 31, 2020 Dec. 31, 2019
$ 1,418,797 $ 1,323,483
436,920 409,219
61,708 118,338
$ 1,917,425 $ 1,851,040
 Note 7 - Notes Payable (Details Textual) - USD ($) Feb. 28, 2018 Mar. 31, 2020
Interest Expense, Total $ 1,142
Senior Notes [Member]
Proceeds from Notes Payable, Total $ 50,000
Debt Instrument, Interest Rate, Stated Percentage 5.00%
Long-Term Debt, Maturity, Remainder of Fiscal Year 8,964
Long-Term Debt, Maturity, Year Two 12,487
Long-Term Debt, Maturity, Year Three 13,126
Long-Term Debt, Maturity, Year Four 2,252
Interest Expense, Total $ 485
Mar. 31, 2019
$ 1,128

$ 621
 Note 8 - Commitments (Details Textual)
Area of Real Estate Property (Square Foot) | ft²
Operating Leases, Rent Expense, Total
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Lessee, Operating Lease, Liability, Payments, Due Year Two
Lessee, Operating Lease, Liability, Payments, Due Year Three
Unrecorded Unconditional Purchase Obligation, Total
 3 Months Ended
Mar. 31, 2020USD ($)ft² Mar. 31, 2019USD ($)
8,400
$ 41,539 $ 40,316
124,616
171,213
176,356
$ 539,000
 Note 9 - Stockholders' Equity (Details Textual)
Preferred Stock, Shares Authorized (in shares)
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares
Preferred Stock, Shares Outstanding, Ending Balance (in shares)
Stock Issued During Period, Shares, Issued for Services (in shares)
Stock Issued During Period, Value, Issued for Services | $
Conversion of Stock, Shares Converted | $
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense | $
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)
Conversion of Stock, Shares Issued (in shares)
Conversion of Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)
Conversion of Stock, Shares Issued (in shares)
Conversion of Series H and Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares
Preferred Stock, Shares Outstanding, Ending Balance (in shares)
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares
Series H Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)
Series I Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)
Series J Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares
Stock Issued During Period, Shares, New Issues (in shares)
Proceeds from Issuance of Preferred Stock and Preference Stock | $
Jan. 24, 2020USD ($)$ / sharesshares Jan. 21, 2020 Apr. 30, 2019

2,000 500

$2
300
$ 300,000
Mar. 31, 2020USD ($)$ / sharesshares Mar. 31, 2019USD ($) Dec. 31, 2019$ / sharesshares
10,000,000 10,000,000
$ 0.01 $ 0.01
400 2,486
10,417
$ 6,000
0
6,000 $ 126,572

$0 $ 26,652

1,686
9,393,937

700
4,087,412

13,481,349

$ 1,000
100 100
$ 350,000

0 1,686

0 700

300
 Note 9 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($) Mar. 31, 2020
Preferred stock, shares outstanding (in shares) 400
Preferred Stock $ 376,095
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares) 100
Preferred Stock $ 76,095
Series H Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares) 0
Preferred Stock
Series I Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares) 0
Preferred Stock
Series J Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares) 300
Preferred Stock $ 300,000
Dec. 31, 2019
2,486
$ 1,932,433

100
$ 76,095

1,686
$ 1,156,338

700
$ 700,000
 Note 9 - Stockholders' Equity - Summary of Warrants (Details)
Series G Warrants [Member]
Exercise price (in dollars per share) | $ / shares
Number of warrants (in shares) | shares
Series H Warrants [Member]
Exercise price (in dollars per share) | $ / shares
Number of warrants (in shares) | shares
Series I Warrants [Member]
Exercise price (in dollars per share) | $ / shares
Number of warrants (in shares) | shares
Mar. 31, 2020$ / sharesshares

$ 25,440
48

$ 1.15
217,392

$ 15,000
48
 3 Months Ended
Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands
Mar. 31, 2020
Income Taxes Paid $0
3 Months Ended
Mar. 31, 2019
$0
 3 Months Ended
Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($)
Mar. 31, 2020
Revenue from Contract with Customer, Including Assessed Tax $ 715,977
Unused Grant Funds 606,944
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax 654,021
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax $ 61,956
3 Months Ended
Mar. 31, 2019
$ 364,232

354,319

$ 9,913
 Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member]
Proceeds From Paycheck Protection Program Under CARES Act
Paycheck Protection Program Loan [Member]
Debt Instrument, Periodic Payment, Total
Apr. 17, 2020USD ($)
$ 170,200

$ 9,578.16